New drug cocktail aims to shrink Hard-to-Treat thyroid tumors
NCT ID NCT07193186
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 36 times
Summary
This phase II trial tests two drugs—anlotinib and benmelstobart—as a second-line treatment for people with advanced or metastatic differentiated thyroid cancer that has not responded to first-line therapy. The study will enroll 23 participants and measure how many see their tumors shrink. Treatment continues until the disease worsens or side effects become too severe.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THYROID CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Anlotinib and Benmelstobart
What this could lead to
If successful, this combination could offer a new second-line treatment option for people with advanced thyroid cancer that has stopped responding to initial therapy.
What could go wrong
This is a small, early-phase (phase II) study with only 23 participants. The treatment may not work for everyone and could cause side effects like fatigue, high blood pressure, or immune-related reactions.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.